/BOLT
BOLT Stock - Bolt Biotherapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$5.98+2.93%
+$0.17 (+2.93%) • Jan 13
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.68
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).84
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+17.1%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BOLT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.92 – $6.04
TARGET (TP)$7.00
STOP LOSS$5.50
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.91
52W High$11.70
52W Low$4.41
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.69M | $7.88M | $5.73M | $1.26M | $231,000 |
| Gross Profit | $7.69M | $-53,666,000 | $-67,394,000 | $-74,395,000 | $-40,126,000 |
| Gross Margin | 100.0% | -681.4% | -1176.4% | -5904.4% | -17370.6% |
| Operating Income | $-73,048,000 | $-76,196,000 | $-90,321,000 | $-92,788,000 | $-49,182,000 |
| Net Income | $-63,118,000 | $-69,197,000 | $-88,098,000 | $-98,591,000 | $-60,728,000 |
| Net Margin | -820.8% | -878.6% | -1537.8% | -7824.7% | -26289.2% |
| EPS | $-1.65 | $-1.83 | $-2.30 | $-2.79 | $-1.99 |
Company Overview
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$7
Average Target
↑ 17.1% Upside
Now
$7
Low
$7
Average
$7
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | H.C. Wainwright | Resumed | Buy | $7 |
Earnings History & Surprises
BOLTBeat Rate
53%
Last 19 quarters
Avg Surprise
+2.7%
EPS vs Estimate
Beats / Misses
10/6
3 met exactly
Latest EPS
$-3.72
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.47vs$-0.47
Q2 24
+45.1%
$-0.28vs$-0.51
Q3 24
-3.7%
$-0.56vs$-0.54
Q4 24
-11.1%
$-0.40vs$-0.36
Q1 25
0.0%
$-7.60vs$-7.60
Q2 25
+14.7%
$-5.80vs$-6.80
Q3 25
+30.3%
$-4.46vs$-6.40
Q4 25
+26.6%
$-3.72vs$-5.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-4.27 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-5.07 | $-3.72 | +26.6% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-6.40 | $-4.46 | +30.3% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-6.80 | $-5.80 | +14.7% | ✓ BEAT |
Q1 2025 | Mar 24, 2025 | $-7.60 | $-7.60 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-0.36 | $-0.40 | -11.1% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.54 | $-0.56 | -3.7% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.51 | $-0.28 | +45.1% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.47 | $-0.47 | 0.0% | = MET |
Q4 2023 | Nov 9, 2023 | $-0.49 | $-0.43 | +12.2% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.53 | $-0.48 | +9.4% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.49 | $-0.45 | +8.2% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-0.63 | $-0.53 | +15.9% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.56 | $-0.58 | -3.6% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.68 | $-0.61 | +10.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.71 | $-0.64 | +9.9% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.66 | $-0.73 | -10.6% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.63 | $-0.63 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-0.38 | $-0.64 | -68.4% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.64 | $-0.86 | -34.4% | ✗ MISS |
Latest News
Bolt Biotherapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS (FOR THE TREATMENT OF CANCER)".
📈 PositiveBenzinga•Dec 8, 2025, 10:03 PM
Bolt Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 13, 2025, 02:18 PM
Bolt Biotherapeutics Q3 EPS $(3.72) Beats $(5.53) Estimate, Sales $2.169M Beat $725.000K Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:30 PM
HC Wainwright & Co. Assumes Bolt Biotherapeutics at Buy, Announces Price Target of $7
📈 PositiveBenzinga•Oct 20, 2025, 10:44 AM
Bolt Biotherapeutics Says Initial Phase 1 BDC-4182 Dose Escalation Data Now Expected In Q3 2026, Implements 50% Workforce Cut
📉 NegativeBenzinga•Oct 1, 2025, 08:06 PM
Frequently Asked Questions about BOLT
What is BOLT's current stock price?
Bolt Biotherapeutics, Inc. (BOLT) is currently trading at $5.98 per share. The stock has moved +2.93% today.
What is the analyst price target for BOLT?
The average analyst price target for BOLT is $7.00, based on 1 analyst.
What sector is Bolt Biotherapeutics, Inc. in?
Bolt Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BOLT's market cap?
Bolt Biotherapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does BOLT pay dividends?
No, Bolt Biotherapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
CING
Cingulate Inc.
$4.87
Mkt Cap: $0.0B
CLRB
Cellectar Biosciences, Inc.
$3.77
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.07
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.58
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$2.23
Mkt Cap: $0.0B
LYRA
Lyra Therapeutics, Inc.
$1.81
Mkt Cap: $0.0B
MRKR
Marker Therapeutics, Inc.
$1.71
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.94
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$11.52
Mkt Cap: $0.0B
Explore stocks similar to BOLT for comparison